Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 06, 2023

BUY
$0.12 - $0.5 $171 - $715
1,430 Added 6.04%
25,121 $3,000
Q2 2023

Jul 27, 2023

SELL
$0.43 - $0.65 $236 - $358
-551 Reduced 2.27%
23,691 $12,000
Q1 2023

May 02, 2023

SELL
$0.46 - $0.81 $144 - $254
-314 Reduced 1.28%
24,242 $15,000
Q4 2022

Feb 09, 2023

BUY
$0.5 - $261.0 $1,232 - $643,104
2,464 Added 11.15%
24,556 $15,000
Q3 2022

Nov 02, 2022

SELL
$1.04 - $322.5 $4,157 - $1.29 Million
-3,998 Reduced 15.32%
22,092 $38,000
Q2 2022

Aug 01, 2022

SELL
$0.41 - $1.24 $82 - $249
-201 Reduced 0.76%
26,090 $32,000
Q1 2022

May 04, 2022

SELL
$0.62 - $1.17 $464 - $876
-749 Reduced 2.77%
26,291 $14,000
Q4 2021

Feb 07, 2022

SELL
$1.09 - $1.89 $830 - $1,440
-762 Reduced 2.74%
27,040 $29,000
Q3 2021

Nov 02, 2021

BUY
$1.44 - $2.73 $912 - $1,730
634 Added 2.33%
27,802 $51,000
Q2 2021

Aug 03, 2021

SELL
$2.63 - $3.67 $1,009 - $1,409
-384 Reduced 1.39%
27,168 $72,000
Q1 2021

May 04, 2021

SELL
$2.82 - $5.6 $4,303 - $8,545
-1,526 Reduced 5.25%
27,552 $99,000
Q4 2020

Feb 01, 2021

BUY
$2.09 - $3.09 $3,137 - $4,638
1,501 Added 5.44%
29,078 $73,000
Q3 2020

Nov 09, 2020

SELL
$2.39 - $3.43 $3,843 - $5,515
-1,608 Reduced 5.51%
27,577 $69,000
Q2 2020

Aug 07, 2020

SELL
$2.2 - $3.71 $2,354 - $3,969
-1,070 Reduced 3.54%
29,185 $96,000
Q1 2020

May 04, 2020

SELL
$1.9 - $4.98 $46,170 - $121,014
-24,300 Reduced 44.54%
30,255 $74,000
Q4 2019

Feb 06, 2020

BUY
$3.95 - $5.35 $18,170 - $24,610
4,600 Added 9.21%
54,555 $257,000
Q4 2019

Feb 04, 2020

BUY
$3.95 - $5.35 $59,510 - $80,603
15,066 Added 43.18%
49,955 $197,000
Q3 2019

Nov 12, 2019

BUY
$4.13 - $6.94 $144,091 - $242,129
34,889 New
34,889 $149,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $458M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.